MRGPR X4 Modulators for Cholestatic Pruritus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic itch conditions, inflammation disorders, and autoimmune diseases mediated by Mas-related G-protein coupled receptor X4 (MRGPR X4) lack effective modulators, particularly for conditions triggered by elevated bilirubin and urobilin levels.
Innovation Solution
Development of compounds with specific structures, such as those represented by Formula (I), which modulate MRGPR X4 by acting as inverse agonists or competitive antagonists, selectively targeting MRGPR X4 to block activation by bilirubin, bile acids, and urobilin, thereby treating associated conditions like cholestatic pruritus and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for chronic itch conditions mediated by MRGPR X4, then current standard therapies can be applied, but effective modulation of MRGPR X4 is not achieved
Solution Approach 1:
The patent modifies the chemical structure of compounds by changing specific parameters (substituents at positions R1-R9, ring sizes, functional groups) to optimize binding affinity and selectivity for MRGPR X4. This systematic parameter variation enables the development of modulators that effectively target MRGPR X4 while maintaining safety profiles.
Solution Approach 2:
The invention introduces local structural features at specific positions in the molecular structure (such as the isoindolinone core with specific substituent patterns at R1-R9) to achieve localized binding characteristics that are selective for MRGPR X4. This local optimization allows the compound to interact specifically with the receptor while avoiding off-target effects.
2Adaptability or versatility
If non-selective modulators are used, then broader receptor coverage is achieved, but specificity for MRGPR X4 is lost
Solution Approach 1:
The patent employs local structural features at specific positions in the molecular structure (such as the isoindolinone core with specific substituent patterns at R1-R9) to achieve localized binding characteristics that are selective for MRGPR X4. This local optimization allows the compound to interact specifically with the receptor while avoiding off-target effects.
Solution Approach 2:
The invention introduces specific parameter variations including the isoindolinone ring system with controlled substituents at R1-R9 positions to achieve selective binding to MRGPR X4. These parameter changes create steric and electronic characteristics that favor interaction with MRGPR X4 over other MRGPR subtypes.
3Reliability
If compounds with high binding affinity are developed, then modulation effectiveness is improved, but safety and tolerability may be compromised
Solution Approach 1:
The patent employs local structural features at specific positions in the molecular structure (such as the isoindolinone core with specific substituent patterns at R1-R9) to achieve localized binding characteristics that are selective for MRGPR X4. This local optimization allows the compound to interact specifically with the receptor while avoiding off-target effects.
Solution Approach 2:
The invention introduces specific parameter variations including the isoindolinone ring system with controlled substituents at R1-R9 positions to achieve selective binding to MRGPR X4. These parameter changes create steric and electronic characteristics that favor interaction with MRGPR X4 while maintaining safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively alleviate itch and pain sensations, treat autoimmune disorders, and address conditions associated with elevated bilirubin and urobilin levels by selectively modulating MRGPR X4, providing a therapeutic option for chronic itch and inflammation disorders.
Implementation Method 1
compounds with specific structures, such as those represented by Formula (I), which modulate MRGPR X4 by acting as inverse agonists or competitive antagonists, selectively targeting MRGPR X4 to block activation by bilirubin, bile acids, and urobilin
Data Source
AI summary
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.